Publications

See Google Scholar here.

2024.

• Iketani S, Ho DD. (2024). SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs. Cell Chemical Biology 31(4):632-657.

2023.

• Wang Q, Guo Y, Liu L, Schwanz LT, Li Z, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Gordon A, Wang HH, Liu L, Ho DD. (2023). Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature 624(7992): 639-644.
  

• Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L, Ho DD. (2023). Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience 26(11): 108254.
  

• Liu L#, Casner RG#, Guo Y#, Wang Q#, Iketani S#, Chan JF#, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. (2023). Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity 56(10): 2442-2455.
  

• Duan Y#, Zhou H#, Liu X#, Iketani S#, Lin M#, Zhang X, Bian Q, Wang H, Sun H, Hong SJ, Culbertson B, Mohri H, Luck MI, Zhu Y, Liu X, Lu Y, Yang X, Yang K, Sabo Y, Chavez A, Goff SP, Rao Z, Ho DD, Yang H. (2023). Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature 622(7982): 376-382.
  

• Cable J, Balachandran S, Daley-Bauer LP, Rustagi A, Antony F, Frere JJ, Strampe J, Kedzierska K, Cannon JL, McGargill MA, Weiskopf D, Mettelman RC, Niessl J, Thomas PG, Briney B, Valkenburg SA, Bloom JD, Bjorkman PJ, Iketani S, Rappazzo CG, Crooks CM, Crofts KF, Pöhlmann S, Krammer F, Sant AJ, Nabel GJ, Schultz-Cherry S. (2023). Viral immunity: Basic mechanisms and therapeutic applications-a Keystone Symposia report. Annals of the New York Academy of Sciences 1521(1): 32-45.
  

• Wang Q#, Iketani S#, Li Z#, Liu L#, Guo Y#, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. (2023). Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186(2): 279-286.
  

• Iketani S#, Mohri H#, Culbertson B#, Hong SJ#, Duan Y, Luck MI, Annavajhala MK, Guo Y, Sheng Z, Uhlemann AC, Goff SP, Sabo Y, Yang H, Chavez A, Ho DD. (2023). Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613(7944): 558-564.

2022.

• Wang Q#, Iketani S#, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L, Ho DD. (2022). Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host & Microbe 30(11): 1512-1517.
  

• Mathema B, Chen L, Wang P, Cunningham MH, Mediavilla JR, Chow KF, Luo Y, Zhao Y, Composto K, Zuckerman J, Zody MC, Wilson N, Lee A, Oschwald DM, Liu L, Iketani S, Germer S, Fennessey S, Wang M, Kramer Y, Toole P, Maniatis T, Ho DD, Perlin DS, Kreiswirth BN. (2022). Genomic Epidemiology and Serology Associated with a SARS-CoV-2 R.1 Variant Outbreak in New Jersey. mBio 13(5): e0214122.
  

• Iketani S#, Hong SJ#, Sheng J#, Bahari F#, Culbertson B, Atanaki FF, Aditham AK, Kratz AF, Luck MI, Tian R, Goff SP, Montazeri H, Sabo Y, Ho DD, Chavez A. (2022). Functional map of SARS-CoV-2 3CL protease reveals tolerant and immutable sites. Cell Host & Microbe 30(10): 1354-1362.
  

• Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L, Ho DD. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608(7923): 603-608.
  

• Wang Q, Anang S, Iketani S, Guo Y, Liu L, Katsamba PS, Shapiro L, Ho DD, Sodroski JG. (2022). Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. Cell Reports 39(11): 110924.
  

• Liu L#, Iketani S#, Guo Y#, Reddem ER#, Casner RG#, Nair MS#, Yu J#, Chan JF#, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L, Ho DD. (2022). An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine 14(646): eabn6859.
  

• Liu H, Iketani S, Zask A, Khanizeman N, Bednarova E, Forouhar F, Fowler B, Hong SJ, Mohri H, Nair MS, Huang Y, Tay NES, Lee S, Karan C, Resnick SJ, Quinn C, Li W, Shion H, Xia X, Daniels JD, Bartolo-Cruz M, Farina M, Rajbhandari P, Jurtschenko C, Lauber MA, McDonald T, Stokes ME, Hurst BL, Rovis T, Chavez A, Ho DD, Stockwell BR. (2022). Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19. Nature Communications 13(1): 1891.
  

• Iketani S#, Liu L#, Guo Y#, Liu L#, Chan JF#, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z, Ho DD. (2022). Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604(7906): 553-556.
  

• Wang P, Casner RG, Nair MS, Yu J, Guo Y, Wang M, Chan JF, Cerutti G, Iketani S, Liu L, Sheng Z, Chen Z, Yuen KY, Kwong PD, Huang Y, Shapiro L, Ho DD. (2022). A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerging Microbes & Infection 11(1): 147-157.
  

• Liu L#, Iketani S#, Guo Y#, Chan JF#, Wang M#, Liu L#, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY, Ho DD. (2022). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602(7898): 676-681.

2021.

• Iketani S#, Liu L#, Nair MS, Chandrashekar A, Mohri H, Wang M, Barouch DH, Huang Y, Ho DD. (2021). Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination. Emerging Microbes & Infection 10(1): 2220-2222.
  

• Resnick SJ, Iketani S, Hong SJ, Zask A, Liu H, Kim S, Melore S, Lin FY, Nair MS, Huang Y, Lee S, Tay NES, Rovis T, Yang HW, Xing L, Stockwell BR, Ho DD, Chavez A. (2021). Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity. Journal of Virology 95(14): e0237420.
  

• Iketani S, Forouhar F, Liu H, Hong SJ, Lin FY, Nair MS, Zask A, Huang Y, Xing L, Stockwell BR, Chavez A, Ho DD. (2021). Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors. Nature Communications 12(1): 2016.
  

• Wang P#, Nair MS#, Liu L#, Iketani S#, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, Ho DD. (2021). Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593(7857): 130-135.

2020.

• Huang J, Zhou J, Ghinnagow R, Seki T, Iketani S, Soulard D, Paczkowski P, Tsuji Y, MacKay S, Cruz LJ, Trottein F, Tsuji M. (2020). Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice. Frontiers in Immunology 11: 2043.
  

• Rathore A, Iketani S, Wang P, Jia M, Sahi V, Ho DD. (2020). CRISPR-based gene knockout screens reveal deubiquitinases involved in HIV-1 latency in two Jurkat cell models. Scientific Reports 10(1): 5350.
  

• Coelho-Dos-Reis JGA, Funakoshi R, Huang J, Pereira FV, Iketani S, Tsuji M. (2020). Functional Human CD141+ Dendritic Cells in Human Immune System Mice. Journal of Infectious Diseases 221(2): 201-213.

2016-2019.

• Miyake Y, Keusch JJ, Decamps L, Ho-Xuan H, Iketani S, Gut H, Kutay U, Helenius A, Yamauchi Y. (2019). Influenza virus uses transportin 1 for vRNP debundling during cell entry. Nature Microbiology 4(4): 578-586.
  

• Iketani S#, Shean RC#, Ferren M#, Makhsous N, Aquino DB, des Georges A, Rima B, Mathieu C, Porotto M, Moscona A, Greninger AL. (2018). Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation. mBio 9(4): e00898-18.
  

• Callaway HM, Welsch K, Weichert W, Allison AB, Hafenstein SL, Huang K, Iketani S, Parrish CR. (2018). Complex and Dynamic Interactions between Parvovirus Capsids, Transferrin Receptors, and Antibodies Control Cell Infection and Host Range. Journal of Virology 92(13): e00460-18.
  

• Organtini LJ, Lee H, Iketani S, Huang K, Ashley RE, Makhov AM, Conway JF, Parrish CR, Hafenstein S. (2016). Near-Atomic Resolution Structure of a Highly Neutralizing Fab Bound to Canine Parvovirus. Journal of Virology 90(21): 9733-9742.
  

• Feng KH, Sun M, Iketani S, Holmes EC, Parrish CR. (2016). Comparing the functions of equine and canine influenza H3N8 virus PA-X proteins: Suppression of reporter gene expression and modulation of global host gene expression. Virology 496: 138-146.